Matea Hunić, R. Teparić, Monika Kovačević, Lidija Barišić
{"title":"新冠肺炎大流行第一年的氯喹故事","authors":"Matea Hunić, R. Teparić, Monika Kovačević, Lidija Barišić","doi":"10.15255/kui.2021.072","DOIUrl":null,"url":null,"abstract":"The emergence of COVID-19 has caused worldwide concern due to its high infectivity and mortality. Research groups around the world have prioritised drug development against COVID-19. Repurposing of already approved drugs, including the antimalarial drug chloroquine, has attracted considerable attention. The aim of this article is to (i) provide an overview of the recent chemical methods used to synthesise chloroquine and hydroxychloroquine, and (ii) provide insight into the data collected in 2020 on their efficacy against COVID-19. Unfortunately, the promising early results have not been confirmed and a clear and unambiguous conclusion on their clinical efficacy has not yet been drawn. (English) [ FROM AUTHOR] Pojava COVIDA-19 uzrokovala je globalnu zabrinutost zbog visoke zaraznosti i mortaliteta. Stoga je razvoj lijekova protiv COVIDA-19 postao prioritet istraživačkim skupinama diljem svijeta. Pri tom je posebnu pozornost privukla moguća prenamjena prethodno odobrenih lijekova, uključujući i antimalarijski lijek klorokin. Cilj ovog rada je (i) prikazati pregled recentnih kemijskih metoda primijenjenih za sintezu klorokina i hidroksiklorokina te (ii) dati uvid u podatke o njihovoj učinkovitosti protiv COVIDA-19 prikupljene tijekom 2020. Nažalost, početni obećavajući rezultati nisu potvrđeni, a jasni i nedvosmisleni zaključci o kliničkoj učinkovitosti klorokina i hidroksiklorokina još nisu postignuti. (Croatian) [ FROM AUTHOR] Copyright of Kemija u Industriji is the property of Croatian Society of Chemical Engineers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Chloroquine Story in the First Year of the COVID-19 Pandemic\",\"authors\":\"Matea Hunić, R. Teparić, Monika Kovačević, Lidija Barišić\",\"doi\":\"10.15255/kui.2021.072\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The emergence of COVID-19 has caused worldwide concern due to its high infectivity and mortality. Research groups around the world have prioritised drug development against COVID-19. Repurposing of already approved drugs, including the antimalarial drug chloroquine, has attracted considerable attention. The aim of this article is to (i) provide an overview of the recent chemical methods used to synthesise chloroquine and hydroxychloroquine, and (ii) provide insight into the data collected in 2020 on their efficacy against COVID-19. Unfortunately, the promising early results have not been confirmed and a clear and unambiguous conclusion on their clinical efficacy has not yet been drawn. (English) [ FROM AUTHOR] Pojava COVIDA-19 uzrokovala je globalnu zabrinutost zbog visoke zaraznosti i mortaliteta. Stoga je razvoj lijekova protiv COVIDA-19 postao prioritet istraživačkim skupinama diljem svijeta. Pri tom je posebnu pozornost privukla moguća prenamjena prethodno odobrenih lijekova, uključujući i antimalarijski lijek klorokin. Cilj ovog rada je (i) prikazati pregled recentnih kemijskih metoda primijenjenih za sintezu klorokina i hidroksiklorokina te (ii) dati uvid u podatke o njihovoj učinkovitosti protiv COVIDA-19 prikupljene tijekom 2020. Nažalost, početni obećavajući rezultati nisu potvrđeni, a jasni i nedvosmisleni zaključci o kliničkoj učinkovitosti klorokina i hidroksiklorokina još nisu postignuti. (Croatian) [ FROM AUTHOR] Copyright of Kemija u Industriji is the property of Croatian Society of Chemical Engineers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)\",\"PeriodicalId\":0,\"journal\":{\"name\":\"\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0,\"publicationDate\":\"2022-07-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15255/kui.2021.072\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15255/kui.2021.072","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
新冠肺炎的出现因其高传染性和高死亡率而引起了全世界的关注。世界各地的研究小组已优先考虑针对新冠肺炎的药物开发。重新利用已经批准的药物,包括抗疟药物氯喹,引起了相当大的关注。本文的目的是(i)概述用于合成氯喹和羟氯喹的最新化学方法,以及(ii)深入了解2020年收集的关于其对新冠肺炎疗效的数据。不幸的是,有希望的早期结果尚未得到证实,也尚未就其临床疗效得出明确无误的结论。(英文)[来自作者]新冠肺炎-19引起了全球对高传染率和高死亡率的关注。因此,开发针对新冠肺炎-19的药物已成为世界研究小组的优先事项。特别注意先前授权药物的可能转让,包括抗疟药物氯因子。这项工作的目的是对最近用于合成氯因子和羟基氯因子的化学方法进行综述,并(i)对2020年期间收集的它们对新冠肺炎-19的有效性数据进行分析。不幸的是,最初有希望的结果尚未得到证实,关于氯喹和羟氯喹的临床疗效也尚未得出明确和无意义的结论。(克罗地亚)[来自作者]Kemija u Industriji的版权归克罗地亚化学工程师协会所有,未经版权持有人明确书面许可,不得将其内容复制或通过电子邮件发送到多个网站或发布到listserv。但是,用户可以打印、下载或通过电子邮件发送文章供个人使用。这可能会被删节。对复印件的准确性不作任何保证。用户应参考材料的原始发布版本以获取完整信息。(版权适用于所有人。)
The Chloroquine Story in the First Year of the COVID-19 Pandemic
The emergence of COVID-19 has caused worldwide concern due to its high infectivity and mortality. Research groups around the world have prioritised drug development against COVID-19. Repurposing of already approved drugs, including the antimalarial drug chloroquine, has attracted considerable attention. The aim of this article is to (i) provide an overview of the recent chemical methods used to synthesise chloroquine and hydroxychloroquine, and (ii) provide insight into the data collected in 2020 on their efficacy against COVID-19. Unfortunately, the promising early results have not been confirmed and a clear and unambiguous conclusion on their clinical efficacy has not yet been drawn. (English) [ FROM AUTHOR] Pojava COVIDA-19 uzrokovala je globalnu zabrinutost zbog visoke zaraznosti i mortaliteta. Stoga je razvoj lijekova protiv COVIDA-19 postao prioritet istraživačkim skupinama diljem svijeta. Pri tom je posebnu pozornost privukla moguća prenamjena prethodno odobrenih lijekova, uključujući i antimalarijski lijek klorokin. Cilj ovog rada je (i) prikazati pregled recentnih kemijskih metoda primijenjenih za sintezu klorokina i hidroksiklorokina te (ii) dati uvid u podatke o njihovoj učinkovitosti protiv COVIDA-19 prikupljene tijekom 2020. Nažalost, početni obećavajući rezultati nisu potvrđeni, a jasni i nedvosmisleni zaključci o kliničkoj učinkovitosti klorokina i hidroksiklorokina još nisu postignuti. (Croatian) [ FROM AUTHOR] Copyright of Kemija u Industriji is the property of Croatian Society of Chemical Engineers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)